Agenus BEST
Our goal is to treat cancers with novel combinations
Interest Rank
This rank shows the popularity of this STO page among other STOs.
Rank
# 27
24H
20%
7D
-18.4%
1M
-18.8%
Description
Agenus is an immuno-oncology company designed to deliver innovation with speed for patients with cancer. We have a unique portfolio of antibodies, vaccines, cell therapies (through our AgenTus Therapeutics subsidiary) and adjuvants designed to treat cancers with optimal combinations.
General information
Country of origin:
Most often it is the country whose citizens are the main part of the team, or the country where the main office is located.
United States
Legal
Company name:
Agenus Inc.
Country of incorporation:
Company address:
Asset
Token rights:
Tokens give their owner the right to implement investment interests. It may be dividends, voting rights, etc.
Regulation(s):
U.S. Securities and Exchange Commission (SEC)
- Reg D (506b, 506c) Token details
Symbol:
BEST
Financial information
Fundraising goal:
Maximum goal for total funds raised in an STO.
$100,000,000
Min. investment:
$0
Additional links
Form D Filling
(Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act)
Team members (16)
Garo Armen, PhD
Chairman and CEO
Jennifer Buell, PhD
Chief Operating Officer
Ozer Baysal
Chief Commercial Officer
Julie DeSander
Vice President, Business Development and Alliance Management
Anna Wijatyk, MD
Vice President of Clinical Development
Sunil Gupta, MBBS, FRCPC
Vice President of Regulatory & Pharmacovigilance
Alex Duncan, PhD
Chief Technology Officer
Christian Cortis, PhD
Chief Strategy Officer & Head of Finance
Evan Kearns, J.D.
Vice President & General Counsel
Christine Klaskin
Vice President, Finance & Principal Accounting Officer
Garo H. Armen, PhD
Chairman and CEO
Brian Corvese
Board of Directors
Wadih Jordan
Board of Directors
Ulf Wiinberg
Board of Directors
Timothy R. Wright
Board of Directors
Allison Jeynes-Ellis
Board of Directors
Advisors (4)
Robert Stein, MD, PhD
Senior R&D Advisor
Hagop Youssoufian, MD
Senior Clinical Strategist
Tyler Curiel, MD, MPH
Senior Strategist for Translational and Biomarker Development
Mary K. Pendergast
Advisor
Other STOs
7Pass
Investment vehicle spanning a spectrum of emerging investment opportunities in the cannabis sector
TBA
edeXa
edeXa offers an innovative business blockchain for the supply-chain.
Ended
Fractional Dash Masternodes
With the Fractional Dash Masternodes anyone can participate in Dash governance and receive block rewards.
Ended
Fvndit
Invest in One of the Fastest Growing Economies
TBA